Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Trial of Quantitative Detection Kit for Hsp90α in Hepatic Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02324127
Recruitment Status : Unknown
Verified December 2014 by Protgen Ltd.
Recruitment status was:  Active, not recruiting
First Posted : December 24, 2014
Last Update Posted : December 24, 2014
Sponsor:
Information provided by (Responsible Party):
Protgen Ltd

Brief Summary:
Detect plasma Hsp90α concentration of liver cancer patients, healthy volunteers, benign liver diseases.

Condition or disease Intervention/treatment Phase
Liver Cancer Device: hsp90 Not Applicable

Detailed Description:
Detect plasma Hsp90α concentration of liver cancer patients, healthy volunteers, benign liver diseases, validate accuracy, specificity and sensitivity of Hsp90α kit.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 1100 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Clinical Trial of Quantitative Detection Kit for Hsp90α in Hepatic Cancer
Study Start Date : October 2012
Estimated Primary Completion Date : December 2014
Estimated Study Completion Date : December 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Liver Cancer

Arm Intervention/treatment
Experimental: liver cancer
Detect plasma Hsp90α concentration of liver cancer patients
Device: hsp90
Detect plasma Hsp90α concentration of lung cancer patients
Other Name: biomarker




Primary Outcome Measures :
  1. Hsp90α Concentration of plasma [ Time Frame: 4 months ]
    Detect Hsp90α Concentration(ng/ml) of plasma and calculate the accuracy, specificity and sensitivity of Hsp90α kit



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Liver cancer patients
  • Healthy volunteers,
  • Benign liver diseases patients

Exclusion Criteria:

  • Patients who Previously accepted radiotherapy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02324127


Locations
Layout table for location information
China, Zhejiang
Zhejiang Medical University Cancer Institute and Hospital
Hangzhou, Zhejiang, China
Sponsors and Collaborators
Protgen Ltd
Investigators
Layout table for investigator information
Principal Investigator: Shusen Zhen, MD The first hospital of Zhejiang province

Layout table for additonal information
Responsible Party: Protgen Ltd
ClinicalTrials.gov Identifier: NCT02324127     History of Changes
Other Study ID Numbers: hsp90a2011-05
First Posted: December 24, 2014    Key Record Dates
Last Update Posted: December 24, 2014
Last Verified: December 2014

Additional relevant MeSH terms:
Layout table for MeSH terms
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Liver Diseases